PAYO · Payoneer Global Inc.

The thesis

Payoneer Global is a pending all-cash takeout at $7.40 per share from Nuvei, and the shares trade below that price, so the remaining return is small and depends on regulatory clearance and completion. The 28 October 2026 close was $7.12. The company projects completion for mid-2027, and that event settles the case.

Stockholders adopted the merger agreement on 14 September 2026, with 224,985,441 shares in favor, 2,236,609 against and 54,219 abstaining (Form 8-K, 14 September 2026). Early termination of the US antitrust waiting period under the Hart-Scott-Rodino Act was granted on 28 July 2026 (definitive proxy, 11 August 2026). A search of company and SEC filings after the 16 October 2026 note found no new disclosure on other approvals, litigation rulings or timing. The company's only new items were the 19 October 2026 stablecoin research report and the 22 October 2026 announcement of the results date.

The narrative is saturated: the terms have been public since 15 June 2026, the 14 September 2026 vote closed the last shareholder question, and the shares have moved -0.7% over three months. The price can rise only toward $7.40, so even a deal that completes leaves a modest gain against the S&P 500 over a three-month window. That ceiling is why the conviction rating stays low. No new fact since the prior note changes the rating.

Bullish and bearish views on Payoneer Global Inc.

The bull case on Payoneer Global Inc. (PAYO), in brief: Shareholders have approved the deal. The bear case: Litigation is disclosed and unresolved.

Bull case

• Shareholders have approved the deal. The 14 September 2026 Form 8-K records 224,985,441 votes in favor against 2,236,609 against. The vote removes the shareholder-rejection risk.
• The US antitrust waiting period has ended. Early termination was granted on 28 July 2026, per the 11 August 2026 definitive proxy. Other regulatory approvals remain outstanding.
• The business kept growing during the process. Second-quarter revenue excluding interest income was $222.2 million, up 10% year over year, and payment volume was $23.7 billion, up 15% (company results release, 6 August 2026). Strong standalone results lower the odds that the buyer seeks to renegotiate.
• Break fees protect the target. The company's termination fee is $89,000,000 and the parent's is $165,000,000, per the 11 August 2026 definitive proxy. The larger fee falls on the acquirer.

Bear case

• Litigation is disclosed and unresolved. A Form 8-K filed 8 September 2026 disclosed lawsuits dated 20 August 2026 and 21 August 2026 alleging incomplete proxy disclosure and seeking to enjoin completion (Form 8-K). A court order blocking completion would confirm the risk.
• A long regulatory interval remains. The company projected completion in mid-2027 on 15 June 2026. The outside date is 12 June 2027 and extends to 12 September 2027 if approvals are pending. A longer wait lowers the annualised return on the remaining gap to $7.40.
• Upside is contractually capped. The offer is all cash at $7.40 with no acquirer stock. The 52-week high is $7.18, and the 28 October 2026 close of $7.12 sits 0.8% below it.
• Little new information arrives. The company has held no earnings calls and given no guidance since 6 August 2026. Results come only as a press release and filing.

Price setup

The 28 October 2026 close was $7.12, adjusted for splits and dividends. The 52-week high is $7.18, the 14-day relative strength index is 40.0, and the three-month change is -0.7%. The shares trade in a narrow range under the $7.40 offer price, and the price follows the market's estimate of completion odds and timing rather than the company's operating results.

Crowding evidence is thin. The buyer's price is fixed, so retail enthusiasm cannot lift the shares past the offer. The one near-term event is the third-quarter report on 5 November 2026, which the company confirmed on 22 October 2026. No insider sale or share issuance is reported in the filings reviewed.

Catalysts, next 30 days

• Any Form 8-K on litigation or regulatory approvals. No date is set. A court ruling or an approval announcement would move the odds of completion.
• 12 June 2027: outside date. It falls outside the 30-day window. It matters because it extends to 12 September 2027 if approvals remain pending.

Elapsed catalysts

• 5 November 2026: third-quarter 2026 results. The company said on 22 October 2026 it will report that day. Per the prior note, results arrive as a press release and filing with no conference call. This is the only scheduled read on standalone fundamentals. (passed 1d ago)

What would change the view

The case breaks if the deal is blocked or terminated. A court order enjoining completion in the lawsuits disclosed on 8 September 2026, a denied regulatory approval or a disclosed termination would each end it. A company filing that moves completion guidance past mid-2027 would also weaken it.

A daily close below $6.75 would show the market pricing a materially higher chance that the deal fails. The standing rating would move up only on a clear sign that the buyer will raise its offer, and no filing or news item reviewed shows one.

What it trades with

The shares trade on the deal outcome. Moves in payments and fintech peers matter little while the $7.40 cash price stands. Nuvei's owners are Advent, Novacap and CDPQ, so no public acquirer shares exist to track. A broad market selloff would matter mainly if it raised financing or deal-completion concerns, and no filing reviewed shows such a concern.